Trial
NCT03567616
A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
AbbVie
Collaborators
Celgene
Condition
Multiple Myeloma
Intervention
Venetoclax
Why stopped
Following results of the primary progression-free survival analysis from Study NCT02755597, company-sponsored MM studies were placed on partial clinical hold (PCH). Sponsor did not pursue release of the PCH for this study.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-06-30